TCM
CLPT icon

Triumph Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Triumph Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,509
Closed -$500K – 193
2021
Q2 		$500K Buy
+29,509
New +$570K 0.29% 86

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Triumph Capital Management's CLPT Position: Q3 2021 in Review

Triumph Capital Management sold out of ClearPoint Neuro (CLPT) in Q3 2021, closing a stake of 29,509 shares — an estimated $500K sold.

Triumph Capital Management first reported a position in CLPT in Q2 2021 and held it in 1 quarter. The position peaked at $500K in Q2 2021. 69 funds tracked by Wall St. Rank hold CLPT as of Q3 2021.

  • Triumph Capital Management reported no remaining ClearPoint Neuro position as of Q3 2021 after selling out during the quarter.
  • Triumph Capital Management sold 29,509 ClearPoint Neuro shares in Q3 2021, an estimated $500K.
  • Triumph Capital Management first reported a position in ClearPoint Neuro in Q2 2021 and held it in 1 quarter.
  • Triumph Capital Management's ClearPoint Neuro position peaked at $500K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q3 2021.

Based on Triumph Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.